AHZ chart, page-30

The company moving to phase 2 and increasing their stake in Coridon gives an indication that the company is confident of the outcomes of the phase 1 trial. It will definitely be good to get confirmation of the phase 1 results with regard to immune responses and safety but I would be surprised of anything other than positive results.

While I think this will have an effect on the share price, the market may have already factored in the results being good. There is a long way to go and funds from the CR have provided the financial and moral support for the future of the vaccine studies and trials.

My personal belief is that the market is correcting from the sell offs of the last six months and a change of sentiment based on the take up of the CR. I believe the private placement has already increased the awareness of the company with instos particularly with the diversity of its products and its massive potential. Not like some other bios that rely entirely on vaccines.

Given that Baillieu Holst valued the SP at 25c in March when it was actually 15 cents would give a degree of confidence in the current SP being under-valued and therefore a good time to buy and accumulate.

There will be those that will want to take quick profits but hopefully that will be counteracted by new investors that see the current SP as good value. This has been evidence by the buy and sell queues over the last 2 weeks.

Looking forward to some steady increases but at the same time watching closely to see if there is any change in sentiment.